...we provide real-world clinicopathological characteristics, treatment patterns, and survival outcomes data in patients with KRAS mutation–positive advanced NSCLC (aNSCLC), including those with KRAS G12C and KRAS non-G12C mutations, who received docetaxel as standard-of-care treatment in the second-line and beyond (2L+)....Real-world outcomes were poor in patients with KRAS G12C–mutated aNSCLC treated with 2L+ docetaxel.